MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Author: Tiash Saha

Proportion
Tiash SahaJanuary 18, 2020

Top Companies Leading the Rare Disease Drug Discovery

KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...

Proportion
Tiash SahaDecember 30, 2019

Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)

KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...

Proportion
Tiash SahaAugust 24, 2018

Telemedicine a Blooming Area, Global Investments to Reach ~1 Billion in 2018: Medgenera Report

KEY POINTS About $725.9 million has been invested in telemedicine segment in 2017 by the global investors: Report Telemedicine is ...

Proportion
Tiash SahaJuly 23, 2018

World’s 10 Top-Selling Orphan Drugs 2018

KEY POINTS Here are the 10 top-selling orphan drugs in terms of their worldwide sales in the previous financial year. ...

Proportion
Tiash SahaJuly 19, 2018

Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients

Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.

Proportion
Tiash SahaJuly 9, 2018

Biogen’s Drug BAN2401 Brings in Fresh Hope for Alzheimer’s Treatment

Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.

Proportion
Tiash SahaJune 15, 2018

[QUIZ] Healthcare Industry Knowledge Assessment

Healthcare Industry Knowledge Assessment How well do you know the healthcare industry? Take this assessment to identify your knowledge of ...

Proportion
Tiash SahaJune 13, 2018

10 Potential Drugs in Development for Alzheimer’s Disease (2018)

KEY POINTS Here are the potential Alzheimer’s disease drug candidates in the late stage of clinical development in 2018. Companies ...

Proportion
Tiash SahaJune 11, 2018

FDA Approves Best-Selling Drugs Combo, ‘Venclexta plus Rituxan’ to Treat Two Common Blood Cancers

Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen. It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.

Proportion
Tiash SahaJune 5, 2018

Mylan-Biocon Bags FDA Nod for Biosimilar Drug ‘Fulphila’, Reduces Infection Risk in Cancer Patients

US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.

  • 1
  • 2
  • 3
  • …
  • 9
Privacy Policy Terms Payment Policy Education Contact Us About us